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Gout management as part of secondary cardiovascular 
prevention: comment on the article by Stamp et al
To the Editor:
The article by Stamp and colleagues (1) contributes to 
 confirming the deleterious role of gout in patients with estab-
lished cardiovascular (CV) disease. In this study, patients with 
gout were shown to have a shorter time to readmission, mainly 
for heart failure, though an increased risk of subsequent myo-
cardial infarction, CV- related death and all- cause death has also 
been reported (2). Of interest, these poor outcomes occurred 
despite appropriate CV management. Gout is a disease with 
variable levels of inflammation (3), driven by the deposition of 
monosodium urate crystals. Therefore, its negative impact on 
atherosclerotic disease highlights the potential of managing 
inflammation as a part of secondary CV prevention, as also 
suggested by the results of the Canakinumab Antiinflammatory 
Thrombosis Outcome Study (4).
Some issues about Stamp and colleagues’ study should 
be addressed. The primary explanatory variables—gout 
and serum urate (SU) levels—were recorded only at base-
line, so how gout was managed during follow- up is unknown. 
The authors remarked that almost all participants classi-
fied as having gout were receiving allopurinol, impeding any 
insights into the CV effects of the drug. Despite this ther-
apy, the mean SU level at baseline was 0.42 mmoles/liter, 
and 69.4% of patients had SU levels of >0.36 mmoles/liter, the 
target recommended by the American College of Rheumatology 
(5). Thus, in the majority of participants with gout in this cohort, 
the SU level was not at even the most conservative target. Allop-
urinol doses were not specified in the report, but they appear 
to not be optimal. In the whole sample, having a lower baseline 
SU level was significantly associated with reduced mortality and 
readmissions. No subgroup analysis was performed, probably 
due to size concerns, even though having the data on those with 
gout might be informative.
Normalizing SU levels in gout leads to the removal of urate 
crystals (6,7) and reduction of systemic inflammation (8), which 
could contribute to secondary (4)—and likely primary—CV pre-
vention. Further studies on CV outcomes in gout patients should 
aim to include patients receiving proper gout management.
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Georgia abortion law and our commitment to patients
To the Editor:
On May 7, 2019, Georgia, the home of the American College 
of Rheumatology (ACR), enacted a law that effectively bans abor-
tion in the state. Kentucky, Mississippi, Ohio, Louisiana, Alabama, 
and Missouri recently passed similar laws.
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These laws conflict directly with the most fundamental 
principles of medical practice in a free society—respect for our 
patients, responsibility to practice evidence- based medicine in 
their best interests, and the freedom to do so without political 
interference. The laws not only challenge and disrespect the 
autonomy of patients and their physicians, they also threaten 
patients and physicians with criminal prosecution, up to and 
including prosecution for murder. Among its provisions, the 
Georgia law even allows the state to investigate women who 
miscarry to determine whether their personal behavior contrib-
uted to the miscarriage, in which case they may be prosecuted.
In opposing these laws, we are keenly aware that health care 
professionals, like the rest of the country, have diverse personal 
beliefs regarding abortion. However, those personal beliefs need 
not undermine a principle that should be common to all of us—
that politicians should not interfere in medical decision- making 
and certainly should not threaten physicians and patients who 
do not align with their partisan political agenda. There should be 
no doubt about that principle, no matter which end of the politi-
cal spectrum is involved.
Rheumatologists are trained for, and trusted with, providing 
expert care of women impacted by disorders of the immune sys-
tem, including some that are particularly notable for complica-
tions during pregnancy. These complications typically occur well 
past the 6- week time frame defined by these so- called heartbeat 
laws. Patients with autoimmune rheumatologic disorders require 
vigilance and shared decision- making among patient, rheuma-
tologist, and obstetrician when complications arise, often acutely 
and requiring immediate decisions on management in the best 
interest of the patient.
When we embarked on careers in medicine, we committed to 
honor patient well- being as the first principle that must guide our 
actions. We believe that this oath obligates us not only to serve 
our patients, but also to publicly oppose any law or regulation 
that would interfere with our ability to do so. We are aware that 
the ACR has acknowledged the recent anti- abortion legislation 
and released a general statement of principle (Advocacy News: 
ACR and Anti- Abortion Legislation; https ://www.rheum atolo gy. 
org/Advoc acy/Advoc acy-News). However, the ACR Board of 
Directors did not directly express opposition to these laws, includ-
ing the law in Georgia, where the ACR resides. We hope that the 
ACR will reconsider that decision, and, in the future, will publicly 
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